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Introduction
About half of the patients with acetylcholine-receptor-antibody 
(AChR-Ab)-negative myasthenia gravis (MG) have antibodies 
against muscle-specific tyrosine kinase (MuSK-Ab). Although 
MG patients with MuSK-Ab have similar clinical features to 
patients with AChR-Ab, they show several distinct characteris-
tics such as a predominance of female patients, predominant 
bulbar and neck weakness, more frequent myasthenic crisis, 
and a tendency to develop muscle atrophy.1-4 In addition, MuSK-
Ab-positive MG patients exhibit distinct responses to acetyl-
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Background and PurposezzPatients with muscle-specific tyrosine kinase (MuSK) antibody 
(MuSK-Ab)-positive myasthenia gravis (MG) show distinct responses to acetylcholinesterase 
inhibitors (AChEIs). Although clinical responses to AChEIs in MuSK-Ab MG are reasonably 
well known, little is known about the electrophysiologic responses to AChEIs. We therefore in-
vestigated the clinical and electrophysiologic responses to AChEIs in MuSK-Ab-positive MG 
patients.
MethodszzWe retrospectively reviewed the medical records and electrodiagnostic findings of 
17 MG patients (10 MuSK-Ab-positive and 7 MuSK-Ab-negative patients) who underwent 
electrodiagnostic testing before and after a neostigmine test (NT).
ResultszzThe frequency of intolerance to pyridostigmine bromide (PB) was higher in MuSK-
Ab-positive patients than in MuSK-Ab-negative patients (50% vs. 0%, respectively; p=0.044), 
while the maximum tolerable dose of PB was lower in the former (90 mg/day vs. 480 mg/day, 
p=0.023). The frequency of positive NT results was significantly lower in MuSK-Ab-positive 
patients than in MuSK-Ab-negative patients (40% vs. 100%, p=0.035), while the nicotinic side 
effects of neostigmine were more frequent in the former (80% vs. 14.3%, p=0.015). Repetitive 
compound muscle action potentials (R-CMAPs) developed more frequently after NT in MuSK-
Ab-positive patients than in MuSK-Ab-negative patients (90% vs. 14.3%, p=0.004). The fre-
quency of a high-frequency-stimulation-induced decrement-increment pattern (DIP) was higher 
in MuSK-Ab-positive patients than in MuSK-Ab-negative patients (100% vs. 17.7%, p=0.003).
ConclusionszzThese results suggest that MuSK-Ab-positive MG patients exhibit unique and 
hyperactive responses to AChEIs. Furthermore, R-CMAP and DIP development on a standard 
AChEI dose may be a distinct neurophysiologic feature indicative of MuSK-Ab-positive MG. 
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cholinesterase (AChE) inhibitors (AChEIs), including overt 
worsening of MG symptoms, frequent cholinergic side effects, 
decreased therapeutic responsiveness to AChEIs, and frequent 
negative results of diagnostic AChEI tests.1,2,5 Although it is 
well known that MuSK-Ab-positive MG patients have distinct 
clinical responses to AChEIs, little is known about the electro-
physiologic responses to AChEIs.
Repetitive compound muscle action potentials (R-CMAPs) 
were previously demonstrated in a MuSK-Ab-positive MG pa-
tient taking the standard dose of AChEI.6 R-CMAPs represent 
cholinergic neuromuscular hyperactivity and occur in several 
conditions, such as congenital AChE deficiency, slow-channel 
congenital myasthenic syndrome, and organophosphate poi-
soning.7 Although R-CMAPs may also be observed in MG pa-
tients with AChEI overdose, they are seldom seen in MG pa-
tients taking the standard dose.6 In addition to R-CMAPs, a 
decrement-increment pattern (DIP) elicited by high-frequency 
repetitive nerve stimulation may also be observed in conditions 
with cholinergic neuromuscular hyperactivity, such as organo-
phosphate poisoning.8
Based on the observation that MuSK-Ab-positive MG pa-
tients exhibit distinct responses to AChEIs, we hypothesized 
that MuSK-Ab-positive MG patients are more sensitive than 
MuSK-Ab-negative MG patients to AChEIs. We tested this by 
investigating the clinical and electrophysiologic characteristics 
of MuSK-Ab-positive MG patients who underwent an electro-
diagnostic testing (EDx) before and after a diagnostic neostig-
mine test (NT).
Methods
We retrospectively reviewed the medical records of MG pa-
tients who underwent EDx and NT from 2007 to 2010 at Sev-
erance Hospital, Yonsei University Health System. The evalua-
tion of MG patients in our electrodiagnostic laboratory usually 
involves a clinical evaluation, EDx, and NT. To confirm the 
presence of objective electrophysiologic responsiveness to 
AChEIs, EDx may be repeated 30–45 minutes after neostig-
mine injection at the examiner’s discretion. We selected 17 MG 
patients who underwent anti-AChR and anti-MuSK antibody 
tests and EDx before and after NT. All of the 17 patients under-
went EDx and NT at the initial diagnosis stage. MG was diag-
nosed based on the symptoms and signs of muscle fatigue, dec-
rement responses on low-frequency repetitive nerve stimulation 
(RNS), serum levels of AChR and MuSK antibodies, and im-
provement of muscle fatigue after the intramuscular injection 
of neostigmine. Antibody analyses were performed using com-
mercially available assays (anti-AChR-binding antibody, Seoul 
Clinical Laboratories, Seoul, Korea; anti-MuSK antibody, 
Athena Diagnostics, Worcester, MA, USA). The test for anti-
AChR-binding antibody was considered to be negative if the 
value was ≤0.2 nmol/L. The results of the anti-MuSK antibod-
ies test were categorized into negative (<10 titer units), border-
line (≥10 titer units and <20 titer units), or positive (≥20 titer 
units).
In all 17 patients, EDx included baseline RNS and post-NT 
ulnar nerve stimulation recordings on the abductor digiti mini-
mi (ADM). The RNS was performed according to previously 
described methods on the ADM and flexor carpi ulnaris (FCU) 
muscles with ulnar nerve stimulation at the elbow, on the or-
bicular oculi and nasalis muscles with facial nerve stimulation, 
and on the trapezius muscle with spinal accessory nerve stimu-
lation using the Neuroscreen system (Toennies, Bavaria, Ger-
many) or the Schwarzer topas EMG system (Natus, Bavaria, 
Germany).9,10 A compound muscle action potential (CMAP) 
decrement of ≥10% was considered abnormal. In patients tak-
ing pyridostigmine bromide (PB), the EDx was performed at 
least 12 hours after the last dose. NT was performed after base-
line clinical examination and EDx. The response was evaluated 
at about 30 minutes after the intramuscular injection of neostig-
mine methylsulfate (0.02 mg/kg). Atropine (1 mg) was admin-
istered several minutes before the neostigmine injection. The 
side effects of neostigmine were described. Nausea, vomiting, 
diarrhea, abdominal cramps, increased peristalsis, increased 
salivation, increased bronchial secretions, miosis, and diapho-
resis were regarded as muscarinic side effects, and muscle 
cramps, fasciculation, weakness, and a tightness sensation on 
any part of the body were regarded as nicotinic effects.
The results of EDx were reviewed by two neurologists (H.J.P. 
and H.E.L.) who were blinded to clinical information. The two 
neurologists consensually determined the presence of R-CMAP 
and a DIP on the ADM muscle at normal gain (5 mV/division). 
R-CMAP was defined as a CMAP followed by repetitive dis-
charges that did not exist prior to NT (Fig. 1). A DIP was de-
fined as the pattern of RNS that shows the maximum decre-
ment of amplitude in the second CMAP and then progressive 
recovery of the amplitude from the third CMAP (Fig. 2).
We obtained patients’ background information from their 
medical records, including the age at MG symptom onset, 
symptoms at disease onset, sex, Myasthenia Gravis Foundation 
of America (MGFA) clinical classification, results of anti-
AChR-binding and anti-MuSK antibody tests, follow-up dura-
tion, MGFA postintervention status, maximum tolerable dose 
of PB, maintenance dose of PB, and intolerance to PB. Intoler-
ance to PB was defined as being unable to take PB due to cho-
linergic side effects such as severe muscle fasciculations, ab-
dominal cramps, hypersalivation, or blurred vision. Age and 
disease duration at EDx, RNS results, MG activities of daily 
living (MG-ADL) score, baseline quantitative MG (QMG) 
score, NT results, and side effects of neostigmine were ob-
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tained from EDx reports.
The requirement for obtaining informed consent from the 
study subjects was waived by the institutional review board of 
Severance Hospital.
Statistical analysis
The Mann-Whitney U test and Fisher’s exact test were used to 
compare continuous and categorical variables, respectively. 
All statistical analyses were performed using SPSS version 
18.0 software (SPSS Inc., Chicago, IL, USA). A two-tailed prob-
ability value of p<0.05 was considered statistically signifi-
cant.
Results
The clinical characteristics of the subjects are summarized in 
Table 1. There were ten MuSK-Ab-positive and seven MuSK-
Ab-negative MG patients. Three MuSK-Ab-positive patients 
(prednisolone 10 mg/day; prednisolone 50 mg/day; azathio-
prine 50 mg/day) and two MuSK-Ab-negative MG patients 
(prednisolone 45 mg/day; cyclosporine 200 mg/day) were 
treated with immune-modifying therapy. All MuSK-Ab-posi-
tive MG patients were negative for anti-AChR-binding anti-
body. Four of the seven MuSK-Ab-negative MG patients were 
positive for anti-AChR-binding antibody. The age at disease 
onset, symptoms at disease onset, follow-up duration, and 
maintenance dose of PB did not differ significantly between 
MuSK-Ab-positive and MuSK-Ab-negative patients. The fre-
quency of intolerance to PB was higher in MuSK-Ab-positive 
patients than in MuSK-Ab-negative patients (50% vs. 0%, re-
spectively; p=0.044), while the maximum tolerable dose of PB 
was lower in the former (90 mg/day vs. 480 mg/day, p=0.023).
The results of EDx and NT are summarized in Table 2. The 
age at EDx, disease duration, MG-ADL score, and QMG 
Fig. 1. Recording from the abductor di-
giti minimi muscle. Data are from a sin-
gle muscle-specific tyrosine kinase anti-
body-positive myasthenia gravis patient. 
Repetitive discharges were not seen in 
the baseline electrodiagnostic testing (A 
and B) after the first compound muscle 
action potential (CMAP). Repetitive 
CMAPs were demonstrated after the in-
tramuscular injection of neostigmine 
methylsulfate (0.02 mg/kg) (C–F). On 
repetitive nerve stimulation (RNS) at 3 
Hz, the repetitive discharges after the 
first CMAP were diminished by the sec-
ond stimulation (D). This reduction was 
more definite for 10-Hz RNS (E and F).
A  
B  
C  
D 
E  
F  
5 mV
5 ms
RNS
10 Hz
RNS
10 Hz
RNS
3 Hz
RNS
3 Hz
Fig. 2. Recording from the abductor di-
giti minimi muscle for high-frequency re-
petitive nerve stimulation at 50 Hz for 
1 second before (A) and after (B) neo-
stigmine injection. Data are from a sin-
gle muscle-specific tyrosine kinase-anti-
body-positive myasthenia gravis patient. 
After the intramuscular injection of neo-
stigmine methylsulfate (0.02 mg/kg), 50-
Hz RNS showed a decrement-increment 
pattern that was not demonstrated be-
fore neostigmine injection. After neostig-
mine injection, 50-Hz RNS resulted in 
the amplitude of the second compound 
mascle action potential (CMAP) (arrow) 
being reduced maximally compared to 
the first CMAP (arrowhead), while the 
amplitude progressively recovered from 
the third CMAP (B).
A  B
5 mV
3 ms
RNS
50 Hz
RNS
50 Hz
Baseline After neostigmine
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score did not differ significantly between MuSK-Ab-positive 
and MuSK-Ab-negative patients. Five MuSK-Ab-negative 
patients (71.4%) exhibited abnormal decrement responses dur-
ing baseline RNS in the ADM and FCU, whereas none of the 
MuSK-Ab-positive patients (0%) exhibited abnormal respons-
es (p=0.003). Positive NT results were significantly less fre-
quent in MuSK-Ab-positive patients than in MuSK-Ab-nega-
tive patients (40% vs. 100%, p=0.035). The nicotinic side 
effects of neostigmine were more frequent in MuSK-Ab-posi-
tive patients than in MuSK-Ab-negative patients (80% vs. 
14.3%, p=0.015). After neostigmine injection, R-CMAPs in 
the ADM developed more frequently in MuSK-Ab-positive 
patients than in MuSK-Ab-negative patients (90% vs. 14.3%, 
p=0.004). High-frequency stimulation of the ulnar nerve (50 
Hz for 1 second) was performed after neostigmine injection in 
eight MuSK-Ab-positive and six MuSK-Ab-negative patients; 
the frequency of a DIP was higher in the MuSK-Ab-positive 
patients than in MuSK-Ab negative patients (100% vs. 17.7%, 
p=0.003). R-CMAP was demonstrated in all patients with a 
DIP.
Discussion
The MuSK-Ab-positive MG patients in the present study 
showed several features suggestive of cholinergic neuromus-
cular hyperactivity to AChEIs. Intolerance to PB and nicotinic 
side effects to neostigmine were more frequent in MuSK-Ab-
positive MG patients than in MuSK-Ab-negative patients. The 
maximum tolerable dose of PB was lower in MuSK-Ab-posi-
tive patients, and negative NT results were more frequent in 
MuSK-Ab-positive patients. These findings are consistent 
with those of previous studies.1,2,5 In addition, the present study 
has provided electrophysiologic evidence of cholinergic neu-
romuscular hyperactivity in MuSK-Ab-positive MG patients, 
in whom the frequencies of R-CMAPs and a DIP on the stan-
dard diagnostic dose of neostigmine were significantly higher 
than in MuSK-Ab-negative patients.
R-CMAP is a well-known electrophysiologic feature of 
congenital AChE deficiency, in which deficiency of neuro-
muscular-junction (NMJ) AChE prolongs the exposure of 
AChR to acetylcholine, resulting in prolonged endplate poten-
tials whose amplitude remains above threshold for longer than 
the absolute refractory period of the muscle fiber.11 A DIP is a 
characteristic electrophysiologic feature of acute poisoning by 
Table 1. Clinical characteristics of MG patients with and without MuSK-Ab
Characteristic MuSK- (n=7) MuSK+ (n=10) p*
Onset age, median (range), years 44.0 (23–48) 37.0 (20–52) 0.353
Female, n (%) 3 (42.9) 10 (100) 0.015
AChR-Ab seropositivity, n (%) 4 (57.1) 0 (0) 0.015
Onset symptoms
Ocular, n (%) 4 (57.1) 8 (80.0) 0.314
Bulbofacial, n (%) 3 (42.9) 2 (20.0)
F/U duration, median (range), months 33.0 (22–46) 41.0 (33–70) 0.063
MGFA clinical classification
IIa, n 2 0
IIb, n  2 2
IIIb, n 1 4
IVb, n  1 3
V, n 1 1
MGFA postintervention status at last visit
PR, n 4 3
MM-1, n 0 6
MM-2, n 0 1
MM-3, n 2 0
Worse, n 1 0
Intolerance to PB, n (%) 0 (0) 5 (50.0) 0.044
Maximum tolerable dose of PB, median (range), mg 480 (120–600) 90 (0–480) 0.023
Maintenance dose of PB, median (range), mg 0 (0–240) 0 (0–120) 0.100
*p values were determined using Fisher’s exact test for categorical variables and the Mann-Whitney U test for continuous variables.
AChR-Ab: acetylcholine receptor antibody, F/U: follow up, MG: myasthenia gravis, MGFA: Myasthenia Gravis Foundation of America, 
MM: minimal manifestation, MuSK-Ab: muscle-specific tyrosine kinase antibody, MuSK-: MuSK-antibody negative, MuSK+: MuSK-anti-
body positive, PB: pyridostigmine bromide, PR: pharmacologic remission.
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organophosphate, which induces irreversible AChE inhibition 
and causes an AChE-deficient status in the NMJ.8 Although 
the pathomechanism of a DIP is poorly understood, stimulus-
induced antidromic backfiring and maximal end-plate depolar-
ization after the first stimulation may play important roles in 
the generation of a DIP.8 Thus, an AChE-deficient status is as-
sociated with the generation of R-CMAPs and a DIP. At the 
NMJ, AChE is linked to collagen Q (ColQ), which binds to 
perlecan and MuSK. The ternary complex consisting of ColQ, 
perlecan, and MuSK is important for the synaptic localization 
of AChE at the NMJ. Previous studies did not detect clustering 
of AChE in MuSK-deficient myotubes, and found that the pas-
sive transfer of anti-MuSK antibodies reduced the size and 
density of ColQ at the NMJ of mice.12,13 Based on these re-
sults, the NMJs of MuSK-Ab-positive MG patients are pre-
dicted to be deficient in synaptic AChE, which leads to overre-
action to AChEIs and the generation of R-CMAPs and a DIP. 
In a recent experiment the administration of therapeutic doses 
of neostigmine evoked R-CMAPs in 94% of MuSK-Ab-posi-
tive MG mice but in only 22% of MuSK-Ab-negative MG 
mice.14 Accordingly, our data suggest that R-CMAPs and/or a 
DIP elicited by the standard dose of AChEI represent an 
AChE-deficient status at the NMJ in MuSK-Ab-positive MG 
patients.
One of the MuSK-Ab-negative patients in this study showed 
both R-CMAPs and a DIP. This patient was a 26-year-old 
woman who had mild ptosis, diplopia, and dysarthria with 
fluctuation (MGFA clinical classification IIb), and was nega-
tive for anti-AChR-binding antibodies. Her ptosis and diplopia 
definitely improved after neostigmine injection, but this also 
resulted in side effects of a tightness sensation on the neck, 
fasciculation, and abdominal cramps. Although the assay for 
MuSK antibodies was negative, there was clinical suspicion of 
MuSK-Ab-positive MG. The possibility of a false-negative 
anti-MuSK antibody result was therefore considered in this 
patient.
Because neostigmine methylsulfate acts for longer than 
edrophonium chloride, both clinical and electrophysiological 
responses could be evaluated. However, patients could suffer 
from side effects for longer if these develop after neostigmine 
injection. A standard dose of neostigmine methylsulfate (0.02 
mg/kg) was used to diagnose MG in this study. Although 1 mg 
of atropine was administered several minutes beforehand to 
reduce muscarinic effects, 15 of 17 subjects (88%) exhibited 
adverse responses to neostigmine. The most common musca-
rinic side effects were abdominal cramps and increased peri-
stalsis, and the most common nicotinic side effects were fas-
ciculation and a sensation of neck tightness. The neostigmine 
Table 2. Results of electrodiagnostic and neostigmine testing of MG patients with and without MuSK-Ab
MuSK- (n=7) MuSK+ (n=10) p*
Age at examination, median (range), years 44.0 (26–48) 42.0 (20–57) 0.768
Disease duration, median (range), months 3.0 (1–89) 16.5 (3–302) 0.078
MG-ADL score, median (range) 6.0 (3–14) 9.0 (4–18) 0.170
Baseline QMG score, median (range) 8.0 (4–19) 13.0 (8–26) 0.056
CMAP decrement on RNS of ≥10%
ADM, n (%) 5 (71.4) 0 (0) 0.003
FCU, n (%) 5 (71.4) 0 (0) 0.003
OO, n (%) 5 (71.4) 8 (80.0) 1.000
Nasalis, n (%) 5 (71.4) 10 (100) 0.154
Trapezius, n (%) 5 (71.4) 5 (50.0) 0.622
Neostigmine test
Positivity, n (%) 7 (100) 4 (40.0) 0.035
Side effects of neostigmine
Muscarinic only, n (%) 5 (71.4) 1 (10.0)
Nicotinic only, n (%) 0 (0) 1 (10.0)
Muscarinic and nicotinic, n (%) 1 (14.3) 7 (70.0)
No side effects, n (%) 1 (14.3) 1 (10.0)
R-CMAP, n (%) 1 (14.3) 9 (90.0) 0.004
Ulnar-nerve RNS at 50 Hz for 1 second, n 6 8
DIP, n (%) 1 (17.7) 8 (100) 0.003
*p values were determined using Fisher’s exact test for categorical variables and the Mann-Whitney U test for continuous variables.
ADM: abductor digiti minimi, CMAP: compound muscle action potential, DIP: decrement-increment pattern, FCU: flexor carpi ulnaris, 
MG-ADL: myasthenia gravis activities of daily living, MuSK-Ab: muscle-specific tyrosine kinase antibody, MuSK-: MuSK-antibody nega-
tive, MuSK+: MuSK-antibody positive, OO: orbicularis oculi, QMG: quantitative myasthenia gravis, R-CMAP: repetitive CMAP, RNS: re-
petitive nerve stimulation. 
Cholinergic Neuromuscular Hyperactivity in MuSK MG
124  J Clin Neurol 2014;10(2):119-124
side effects were mild in almost all of the patients, and subsid-
ed within 1 hour without treatment. However, one MuSK-Ab-
positive patient showed severe fasciculation over the entire 
body along with diaphoresis and increased salivation, which 
lasted for 1.5 hours (the patient was observed closely until the 
side effects subsided). This indicates the need to observe pa-
tients closely for at least 1 hour after neostigmine injection.
This study was subject to several limitations. First, the retro-
spective design of the study and the small sample might mean 
that the conclusions are not generalizable. The main reason for 
the small sample in this study is that anti-MuSK antibody as-
say was applied to few of the MG patients due to the inconve-
nience of this assay. Anti-MuSK antibody analysis was per-
formed in the generalized MG patients who had predominant 
bulbar symptoms and/or seronegativity for anti-AChR-binding 
antibody. There is a possibility of selection bias whereby the 
MuSK-Ab-negative group may have included clinically sus-
pected MuSK-Ab-positive patients with false-negative MuSK-
Ab assay results. Second, there was another selection bias 
problem, in that the EDx after NT was applied only to a small 
proportion of the MG patients at the examiner’s discretion. 
Third, since we observed R-CMAPs using a surface record-
ing electrode at normal gain, we could not apply a previously 
used grading system.15 Furthermore, we may have missed R-
CMAPs whose repetitive discharges had very low amplitudes 
following the first CMAP. Even so, all patients with R-CMAPs 
definitely exhibited repetitive discharges, whereas none of 
the patients with no R-CMAP were suspected of exhibiting 
repetitive discharges. Together these limitations mean that 
studies with larger samples and well-designed EDx for de-
tecting and grading R-CMAPs are necessary to validate the 
hypothesis that MuSK-Ab-positive MG patients are more 
sensitive than MuSK-Ab-negative patients to AChEIs.
In conclusion, MuSK-Ab-positive MG patients exhibit 
distinct responses to AChEIs, including intolerance to AChEIs, 
frequent nicotinic side effects, and frequent negative results 
for diagnostic AChEI tests. Furthermore, R-CMAP and DIP 
development on a standard AChEI dose are associated with 
MuSK-Ab-positive MG. These features suggest the presence 
of cholinergic neuromuscular hyperactivity in MuSK-Ab-
positive MG and may be helpful for the diagnosis of MuSK-
Ab-positive MG.
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